Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
6.51 EUR | -0.91% | -3.70% | -1.96% |
May. 21 | Nanobiotix to Transfer Phase 3 Head and Neck Cancer Study Sponsorship | MT |
May. 14 | Nanobiotix to Proceed to Phase 2 Trial of Lung Cancer Treatment | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-1.96% | 336M | |
+44.48% | 54.04B | |
+43.57% | 41.96B | |
-0.86% | 41.92B | |
-7.59% | 28.35B | |
+12.30% | 26.35B | |
-21.83% | 19B | |
+7.15% | 13B | |
+29.40% | 12.28B | |
+25.15% | 12.19B |
- Stock Market
- Equities
- NANO Stock
- News Nanobiotix
- Nanobiotix Appoints Kayitalire as Chief Medical Officer